Gapping up
In reaction to earnings/guidance:
- AVNS +4.7% (guidance), RTX +0.6% (guidance)
Other news:
- DICE +38.4% (Lilly (LLY) to acquire DICE Therapeutics to advance innovation in immunology for $48 per share in cash)
- VERA +8.8% (Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress)
- PGEN +6.6% (Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis)
- ENTA +5% (announces positive data from a phase 1 clinical study of EDP-323, an oral, l-protein inhibitor in development for the treatment of respiratory syncytial virus)
- MIST +3.7% (announces the publication of results in The Lancet from the Phase 3 RAPID clinical trial evaluating etripamil nasal spray, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia)
- NR +3.3% (exploring strategic alternatives for the long-term positioning of its Fluids Systems division)
- SNY +3.1% (prevails in Zantac arbitration initiated by Boehringer Ingelheim)
- RDNT +2.8% (announces closing of public offering of 8.71 mln shares of common stock at price of $29.75/share, which includes entire overallotment option to underwriters of 1.14 mln shares)
- CPRX +2.4% (to license North American rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals)
- PYPL +1.8% (PayPal and KKR (KKR) announce an exclusive multi-year agreement for a €3 billion replenishing loan commitment)
- NKLA +1.7% (announces update on business optimization efforts, including streamlining of operations and decrease in cash spend; to reduce headcount, resulting in decrease in personnel-related cash spend by more than $50 mln annually)
- BF.B +1.7% (divests Finlandia Vodka for $220 mln)
- KEN +1.6% (announces the commencement by OPC's subsidiary CPV Group of construction of a solar power project with a capacity of 170 MW in Maryland, United States, in the PJM market, also called the Backbone project)
- IOVA +1.4% (files mixed securities shelf offering)
- KDNY +1.4% (Presents Data from CHK-336 Phase 1 Trial)
- BBIO +1% (presents updated six month results from its phase 2 cohort 5 trial of infigratinib in Achondroplasia at the Endocrine Society 2023 Annual Conference)
Analyst comments:
- CAR +4.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- MLCO +2.2% (upgraded to Outperform from Neutral at Credit Suisse)
- BIDU +0.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)